Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and nerve impulse transmission. Dextrose 5% provides caloric support and may help prevent ketosis. Sodium chloride 0.3% provides sodium and chloride ions to maintain extracellular fluid volume and electrolyte balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
1 to 2 mEq/kg per day IV, infused at a rate not exceeding 10 mEq/hour; typical adult dose 20-40 mEq per dose.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable for potassium itself; potassium is an electrolyte with no true elimination half-life. Distribution half-life of administered potassium is approximately 1-1.5 hours due to cellular uptake.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal excretion: >90% of potassium load excreted by kidneys; remainder via feces (~10%) and sweat (<5%).
Category C
Category A/B
Electrolyte
Electrolyte